Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025

10/10/25 8:00:00 AM ET

Computer Software: Prepackaged Software

Technology

Get the next $CERT alert in real time by email

RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 after the market close on Thursday, November 6^th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET.

Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance.

A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/.

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.

Investor Relations Contact:

David Deuchler

Gilmartin Group

ir@certara.com

Media Contact:

Alyssa Horowitz

certara@pancomm.com

Get the next $CERT alert in real time by email

Recent Analyst Ratings for

$CERT

Date	Price Target	Rating	Analyst
3/6/2026	$8.00	Overweight → Equal Weight	Barclays
2/27/2026	$10.00	Buy → Hold	Craig Hallum
1/6/2026	$13.00	Market Perform → Outperform	Leerink Partners
11/21/2025	$10.00	Buy	Rothschild & Co Redburn
11/13/2025	$9.00	Market Perform	BMO Capital Markets
9/29/2025	$16.00	Buy	Craig Hallum
7/3/2025	$16.00	Equal-Weight	Morgan Stanley
5/8/2025	$14.00	Equal Weight → Overweight	Barclays

More analyst ratings

Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CERT

Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CERT

$CERT
Insider Trading

Chief Human Resources Officer Anhalt Rona converted options into 7,147 shares and covered exercise/tax liability with 2,241 shares, increasing direct ownership by 41% to 16,789 units (SEC Form 4) (withholding tax)

SVP and General Counsel Corcoran Daniel converted options into 22,830 shares and covered exercise/tax liability with 12,103 shares, increasing direct ownership by 50% to 32,046 units (SEC Form 4) (for tax liability)

Director Bedi Arjun converted options into 5,547 shares (SEC Form 4)

$CERT
Press Releases

Certara Announces CFO Transition

The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

Certara to Participate in Upcoming Investor Conferences

$CERT
Analyst Ratings

Certara downgraded by Barclays with a new price target

Certara downgraded by Craig Hallum with a new price target

Certara upgraded by Leerink Partners with a new price target

$CERT
Insider Purchases

$CERT
SEC Filings

CHIEF EXECUTIVE OFFICER Feehery William F bought $200,000 worth of shares (24,096 units at $8.30), increasing direct ownership by 1% to 2,360,769 units (SEC Form 4)

Certara Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 8-K filed by Certara Inc.

SEC Form 10-Q filed by Certara Inc.

$CERT
Financials

Certara Reports First Quarter 2026 Financial Results

Certara to Report First Quarter 2026 Financial Results on May 11th, 2026

Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance

$CERT
Leadership Updates

The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

Certara Appoints Jon Resnick as Chief Executive Officer

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform

$CERT
Large Ownership Changes

SEC Form SC 13G filed by Certara Inc.

Amendment: SEC Form SC 13G/A filed by Certara Inc.

SEC Form SC 13G/A filed by Certara Inc. (Amendment)

Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $CERT

Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $CERT

$CERT Insider Trading

Chief Human Resources Officer Anhalt Rona converted options into 7,147 shares and covered exercise/tax liability with 2,241 shares, increasing direct ownership by 41% to 16,789 units (SEC Form 4) (withholding tax)

SVP and General Counsel Corcoran Daniel converted options into 22,830 shares and covered exercise/tax liability with 12,103 shares, increasing direct ownership by 50% to 32,046 units (SEC Form 4) (for tax liability)

Director Bedi Arjun converted options into 5,547 shares (SEC Form 4)

$CERT Press Releases

Certara Announces CFO Transition

The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

Certara to Participate in Upcoming Investor Conferences

$CERT Analyst Ratings

Certara downgraded by Barclays with a new price target

Certara downgraded by Craig Hallum with a new price target

Certara upgraded by Leerink Partners with a new price target

$CERT Insider Purchases

$CERT SEC Filings

CHIEF EXECUTIVE OFFICER Feehery William F bought $200,000 worth of shares (24,096 units at $8.30), increasing direct ownership by 1% to 2,360,769 units (SEC Form 4)

Certara Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 8-K filed by Certara Inc.

SEC Form 10-Q filed by Certara Inc.

$CERT Financials

Certara Reports First Quarter 2026 Financial Results

Certara to Report First Quarter 2026 Financial Results on May 11th, 2026

Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance

$CERT Leadership Updates

The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

Certara Appoints Jon Resnick as Chief Executive Officer

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform

$CERT Large Ownership Changes

SEC Form SC 13G filed by Certara Inc.

Amendment: SEC Form SC 13G/A filed by Certara Inc.

SEC Form SC 13G/A filed by Certara Inc. (Amendment)

Recent Analyst Ratings for
$CERT

Recent Analyst Ratings for
$CERT

$CERT
Insider Trading

$CERT
Press Releases

$CERT
Analyst Ratings

$CERT
Insider Purchases

$CERT
SEC Filings

$CERT
Financials

$CERT
Leadership Updates

$CERT
Large Ownership Changes